Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-337933
Filing Date
2026-08-06
Accepted
2026-08-06 16:03:49
Documents
72
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q whwk-20260630.htm   iXBRL 10-Q 3170026
2 EX-31.1 whwk-ex31_1.htm EX-31.1 17091
3 EX-31.2 whwk-ex31_2.htm EX-31.2 17069
4 EX-32.1 whwk-ex32_1.htm EX-32.1 9471
5 EX-32.2 whwk-ex32_2.htm EX-32.2 9457
  Complete submission text file 0001193125-26-337933.txt   11672680

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT whwk-20260630.xsd EX-101.SCH 1260699
76 EXTRACTED XBRL INSTANCE DOCUMENT whwk-20260630_htm.xml XML 2234466
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38560 | Film No.: 261248783
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)